Saenz, D T
Fiskus, W
Manshouri, T
Rajapakshe, K
Krieger, S
Sun, B
Mill, C P
DiNardo, C
Pemmaraju, N
Kadia, T
Parmar, S
Sharma, S
Coarfa, C
Qiu, P
Verstovsek, S
Bhalla, K N
Article History
Received: 20 June 2016
Revised: 15 August 2016
Accepted: 30 August 2016
First Online: 28 September 2016
Competing interests
: Dr Pemmaraju serves on the scientific advisory board of Incyte Pharmaceuticals. He has also served as a consultant and received research funding from Novartis Pharmaceuticals. The other authors declare no conflict of interest.